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Summary Pharmacokinetic and imaging studies in 19 patients receiving liposome-entrapped adriamycin
(L-ADM) were carried out within the framework of a Phase I clinical trial (Gabizon et al., 1989a). The
formulation of L-ADM tested consisted of 0.2gM-extruded multilamellar vesicles composed of egg phos-
phatidylcholine, egg-derived phosphatidyl-glycerol (PG), cholesterol, and ADM intercalated in the fluid lipid
bilayer. Plasma clearance of total drug extracted from the plasma after L-ADM infusion followed a
biexponential curve with a pattern similar to that reported for free ADM. The plasma concentration of drug
circulating in liposome-associated form was also measured in a subgroup of seven patients. Liposome-
associated drug was found to be rapidly cleared from plasma. Its ratio to nonliposome-associated drug
appeared to correlate with liver reserve, with highest ratios in patients with normal liver function. Liposome
clearance, as measured by the plasma concentration of PG in three patients was slower than the clearance of
liposome-associated ADM, suggesting that liposomes lose part of their drug payload during circulation. To
learn about the liposome organ distribution, imaging studies were carried out with "'Indium-deferoxamine
labelled liposomes of the same composition. Liposomes were cleared predominantly by liver and spleen and to
a lesser extent by bone marrow in seven out of nine patients. In two patients with active hepatitis and severe
liver dysfunction, there was minimal liver uptake and increased spleen and bone marrow uptake. Except for
one hepatoma patient, intrahepatic and extrahepatic tumours were not imaged by liposomes, suggesting that
liposome uptake is restricted to cells of the reticulo-endothelial system (RES). These observations indicate that
a major fraction of this L-ADM formulation is rapidly cleared by the RES, and that the mechanism of drug
delivery is probably the combined result of slow release from the RES depot and drug leakage from circulating
liposomes.
Liposome-entrapped adriamycin (L-ADM) has been shown
to have reduced toxicity and preserved or improved anti-
tumour efficacy in experimental animal models (reviewed in
Perez-Soler, 1989; Gabizon, 1989). Recently we have carried
out a Phase I clinical study (Gabizon et al., 1989a) with a
formulation of L-ADM in which the drug is incorporated in
the fluid bilayer of the vesicles (Amselem et al., 1990a). The
results have been consistent with the preclinical observations,
namely the maximal tolerated dose (MTD) of L-ADM was
increased in relation to the MTD of free drug administered
at the conventional 3-weekly schedule. However the dose
limiting toxicity for L-ADM was, as for free ADM, myelo-
toxicity. Thus, although the toxicities of free ADM and
L-ADM differ quantitatively, they are qualitatively similar.
In this report we summarise pharmacokinetic and imaging
studies with L-ADM and radiolabelled liposomes ofthe same
composition in the Phase I study patients and a small group
of additional patients with similar eligibility criteria. The
results point at a very fast elimination rate of the liposome-
associated drug and of the radiolabelled liposomes from
plasma after intravenous injection. The liver and spleen were
recognised as the main organs for liposome clearance. There
was, however, significant variability among the patients.
Patients with impaired liver function had decreased liver
clearance and increased localisation in the bone marrow. At
the same time, higher levels of free drug leaking from circu-
lating liposomes were observed in plasma. There was no
significant tumour uptake of radiolabelled liposomes in intra-
hepatic or extrahepatic tumours, except for one of the hepa-
toma patients.
Materials and methods
Liposomeformulation
The formulation used in this study has been previously de-
scribed (Amselem et al., 1990a). Briefly, it consisted of egg
phosphatidylcholine (PC), phosphatidylglycerol (PG), choles-
terol, and D-alpha tocopherol succinate at a molar ratio of
7: 3: 4: 0.2, respectively. Quality control analysis was done
as previously reported (Amselem et al., 1990b, 1991). Most of
the entrapped ADM was present in the liposome bilayer
(<90%). The final drug to phospholipid ratio was in the
range of 25 to 50 ,g per ytmol. Deferoxamine (DF) was
present in both the intravesicular and extravesicular water
phase at a concentration of 501M. The mean size of the
vesicles as determined by dynamic laser scattering was in the
range of 0.3 to 0.5 gM. The level of unencapsulated ADM
present in the injected batches was less than 10% of the total
ADM concentration. L-ADM was administered at a concent-
ration of 0.5 to 2.0 mg ADM ml-' in physiologic saline and
at a rate of 2 to 3 ml per minute through a peripheral arm
vein. Infusion time ranged between 30 and 90min.
Plasma drug determination andpharmacokinetic analysis.
Ten patients receiving L-ADM were examined for plasma
drug levels of ADM and its active metabolite, adriamycinol
(ADMol). Blood samples were drawn from an arm vein
contralateral to the infusion side before and immediately
after completion of the infusion and at various time intervals
thereafter within the following 24 h. Coagulation was pre-
vented by K3-EDTA. Plasma was separated by centrifugation
and stored at - 20°C. ADM and its metabolites were extract-
ed as described by Andrews et al. (1980). HPLC analysis of
ADM and metabolites was done following the procedure of
Beijnen et al. (1985) with minor modifications as previously
reported (Amselem et al., 1991). A reverse phase column
(RP-C8, Alltech, Deerfields, IL) measuring 150 x 4.6 mm was
used. The column was eluted with a solvent system of aceto-
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nitrile-water (4:6, v/v) containing 10 mg 1-' Desperamine-HCl
to reduce adsorption ofADM to glassware and column. The
pH of the mobile phase was adjusted to 2.5 with perchloric
acid. Quantitation was done fluorometrically using a Jasco
FR-210 spectrofluorometer (excitation, 470 nm; emission,
565 nm). Retention times for ADM and ADMol were 8.18
and 5.23 min respectively. Values were corrected for the per
cent of plasma extraction recovery based on an internal
daunorubicin standard (retention time, 16.70min) added to
plasma samples before processing. Data were analysed using
a Hewlett-Packard 3393a integrator. Curve fitting of post-
infusion plasma time/concentration data was done by non-
linear least squares analysis using Rstrip pharmacokinetic
modelling software (MicroMath Inc., Salt Lake City, Utah).
Pharmacokinetic parameters were calculated using standard
methods (Rowland & Tozer, 1989). Clearance was calculated
by dividing the total dose by the area under the concentra-
tion vs time curve (AUC). Mean residence time was calcul-
ated by dividing the area under the moment curve by the
AUC. The apparent volume of distribution at steady state
was the product of the mean residence time and the clear-
ance.
In seven patients, plasma liposome-associated ADM was
separated from free and protein-bound ADM using a Dowex
cation-exchange resin as previously described (Druckmann et
al., 1989). Plasma was thereafter processed for HPLC drug
analysis as detailed above. Measurements of total and lipo-
some-associated plasma ADM were obtained. The level of
free and protein-bound ADM was inferred by subtracting the
concentration of liposome-associated ADM from that of
total ADM. In three of these patients, we also measured the
concentration of PG in plasma to follow the clearance of
liposomes (Barenholz et al., 1990). PG was selected as a *
liposome marker because of its very low concentration in C
plasma (t5 nmoles ml-') relative to the concentration of
total phospholipids (2,000-4,000 nmolesml-'). Phosphati-
dylethanolamine (PE) was chosen as an internal standard due 2
to its absence in the liposome formulation and its being in a
concentration range of similar order of magnitude to the ,
infused liposomes. Plasma samples were extracted by a
monophasic system of chloroform:methanol:water/plasma
(C:M:H20, 1:2:1 by volume). This was followed by complete 20
trinitrophenylation of the plasma aminolipids (PE, phospha- E
tidylserine) and ADM by trinitrobenzene sulfonate. Lipid
extraction was completed by adding chloroform and water
(C:M:H20 final volume ratio, 1:1:1) to form two phases.
Lipids were recovered in the lower chloroformic phase which
was then evaporated to dryness at room temperature and
chromatographed on low phosphorus silica gel thin layer
plates (Analtech, Newark, NJ, USA) using two solvent
systems both developed in the same direction (diethyether:
glacial acetic acid, 190:10; and C:acetone:M:glacial acetic
acid:H20, 6:8:2:2:1). The spots were scraped after being
identified and their phosphorus content was determined using
the modified Bartlett procedure (Bartlett, 1959). The follow-
ing Rf (distance of compound from origin/distance of solvent
front from origin) values were obtained: neutral lipids, 1.00;
trinitrophenylated ADM, 0.93; trinitrophenylated PE (inter-
nal standard), 0.87; trinitrophenylated PS, 0.78-0.70; PG
(liposome marker), 0.53; PC, 0.13; sphingomyelin, 0.07. The
step of trinitrophenylation was essential to optimise the
chromatographic separation.
Imaging studies
Liposomes of the same lipid composition, but without ADM,
were prepared in the presence of physiologic saline contain-
ing 200gM DF by hydration of a thin lipid film followed by
extrusion throiGah A v sM-nnrp nn1v,nrh.nntt- mtmhrsnnwe -%J%,1 0WiL1V L111VUY,1 V. CA-PU1V P1LZUV1ULCa 111CHllUla4l -
(Amselem et al., 1990b), in a similar way to ADM-containing
liposomes. Unencapsulated DF was removed by passage
through a Dowex cation-exchange resin. Liposomes were
labelled with "'In by incubation with an "'In-oxine (Amer-
sham) complex at room temperature for about 30 min using
a technique similar to the 67Gallium labelling method (Gabi-
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zon et al., 1988). Approximately 90% of the label becomes
associated with liposomes as shown by separation of the
liposomes from the suspension medium by ultracentrifuga-
tion (100,000 g x 30min) and by gel exclusion chromato-
graphy on Biogel A15M columns (Druckman et al., 1989).
Only a minor fraction (A15%) of the liposome-associated
label is removable by incubation with DTPA, a strong "'In
chelator, added to the outer water phase to remove any
accessible "'In associated with the outer leaflet of the exter-
nal bilayer (Essien & Hwang, 1988). This suggests that most
of the liposome label is either associated with the inner
bilayers in the form of a lipophilic "'In-oxine complex or
bound to DF in the inner water phase of the liposomes.
Although the 67Gallium-DF complex is more stable than
"'In-DF (Weiner et al., 1979), we could not test it in this
clinical study since 67Gallium-oxine, needed for the loading
step, is not commercially available in a form approved for
human use.
Patients were imaged using a dose of 5 p700 ICi "'In and
;3O0 mg phospholipid given by i.v. bolus. Whole body an-
terior and posterior images were obtained immediately after
injection, 2 h and 24 h later, using a Gamma camera (Apex
415 Elscint, Haifa, Israel).
1984), subtle differences between free and L-ADM cannot be
discarded unless free and liposome-encapsulated drug are
tested in the same patients and at the same dosage.
The clearance curves of ADM and ADMol in two patients
receiving 50 and 100 mg m2 are shown in Figures la and b.
As seen in Figure 1, the pattern of clearance was similar
despite the different dosage. The metabolite ADMol was
already detectable around 30 min after end of infusion, sug-
gesting that L-ADM rapidly became bioavailable. Figure 2
shows the clearance curves of ADM in patients retreated
with the same dose of L-ADM (Figure 2a) or a lower dose of
L-ADM (Figure 2b). As seen in Figure 2, the plasma ADM
levels obtained after readministration of L-ADM in the same
patient were in accordance with the dosage.
The results described above refer to total plasma ADM
concentrations including liposome-associated, protein-bound,
U
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Results
Patient characteristics
Table I summarises the general characteristics of the patients
from whom pharmacokinetic and imaging data were obtain-
ed. Patient numbers shown in Tables II and III and figure
legends can be cross-checked with patient characteristics
using Table I.
Pharmacokinetic studies
Table II summarises the post-infusion pharmacokinetic para-
meters of ten patients treated with 50 to 120 mg m2 L-
ADM. The plasma clearance of L-ADM after completion of
the infusion was best fitted to a biexponential curve as
reported for free ADM by Greene et al. (1983). The distribu-
tion phase was short with half-lives ranging between 2 and
10.6 min. The terminal clearance phase was characterised by
slowly declining plasma concentrations and a half-life rang-
ing between 11 and 110 h. Except for patient number 1 who
suffered from cirrhosis, there was a trend to a greater AUC
with increasing dose. However, even within the same dose
level (85 or 120 mgm2), there was approximately a 5-fold
variation in AUC between subjects. This highlights the prob-
lem of interpatient variability, as reported for free ADM
(Cummings et al., 1988). Although the pharmacokinetic
parameters in most of the patients receiving L-ADM were of
a similar order of magnitude to those reported for free
ADM, 75 mg m-2 (Greene et al., 1983; Chlebowski et al.,
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Figure 1 Plasma clearance of ADM and ADMol in patients
receiving 50mgm-2 (a, patient number 2) and 100mgm-2 (b,
patient number 7) of L-ADM.
Table II Post-infusion pharmacokinetic parameters ofADM in patients receiving L-ADM
Infusion
Patient Dose time Co AUC o MRT CL Vss
number mgm-2 (min) mgl mghrtV' hr mlmin-kg- I kg-'
1 50 45 2.9 2.5 13.9 9.1 7.6
2 50 45 0.9 0.7 13.1 35.9 28.2
3 70 60 0.6 1.4 15.9 21.4 20.4
4 85 70 1.3 1.8 25.3 20.2 30.7
5 85 60 7.1 3.6 31.8 9.6 18.3
6 85 60 4.6 7.5 135.1 4.8 38.9
7 100 65 3.2 4.6 29.6 11.3 20.0
8 120 42 4.5 2.3 13.8 24.9 20.6
9 120 65 3.3 7.7 38.9 7.1 16.7
10 120 78 6.3 12.7 42.1 3.9 9.9
Co = extrapolatedconcentration attime0(endofinfusion); AUC = areaunderthecurve; MRT = mean
residence time; CL = clearance; Vss = apparent volume ofdistribution at steady state.
In1128 A. GABIZON et al.
a peak levels, and respective ratios of plasma liposome-asso-
Dose: 70 mgM-2 ciated ADM to nonliposome-associated (free and protein- Dose: 70 mg me2 bound) ADM during the infusion and a limited post-infusion
,;* 1sttreatment period. The AUC and peak level ratios differed among the
0 2nd treatment various patients by more than 10-fold. One factor that may
account for this variability is the degree of liver involvement.
The highest ratios were observed in patients with normal
liver function and reserve. Figures 3a and b show the levels
of total, liposome-associated, and nonliposome-associated
ADM in two patients representing the two extreme cases. In - Figure 3a most of the plasma ADM (>90%) was in lipo-
some-associated form at any measured time. In Figure 3b,
, , , , , ;50% of the ADM measured in plasma was in free and
0 4 8 12 16 20 protein-bound form, pointing at significant drug leakage
from the liposomes. It should be noted that the toxicity seen
in the patient represented in Figure 3b (grade 4 myelosup-
pression and grade 4 mucositis) was much more severe and
protracted than that occurring in the patient represented in
b Figure 3a (grade 2 myelosuppression and grade 1 mucositis).
m-2
0
12 16 20
Hours after end of infusion
Figure 2 Plasma clearance of ADM in patients receiving two
successive treatments of L-ADM at the same dose (a, patient
number 3) or at a lower dose (b, patient number 1).
and free drug fractions. The quantitative distribution of
ADM in protein-bound and unbound fractions is known
(Eksborg et al., 1982). However, it is essential to estimate the
fraction in liposome-associated form to assess the true bio-
availability. For instance, the short post-infusion distribution
half-life may be due to rapid clearance of L-ADM by the
RES or to drug leakage followed by rapid distribution into
peripheral tissues. These two processes lead to very different
pharmacological effects. Nonetheless, their plasma kinetics
may look similar if only total drug measurements are made.
Using a cation-exchange hydrophobic resin to remove non-
liposome-associated ADM (Druckmann et al., 1989), we have
directly measured the plasma levels of liposome-associated
ADM in seven patients. These measurements were especially
valuable during the infusion time and during the first hour
after the end of the infusion. Thereafter, the levels of
liposome-associated ADM were very low, as those of total
plasma ADM, and were probably ofminor significance in the
pharmacokinetic analysis. Table III presents the AUC values,
E
CD
0
a
0
0
0
.,_
E C)
(L
Minutes after start of infusion
Figure 3 Plasma clearance of total ADM (0-0), liposome-
associated ADM (A--A), and nonliposome-associated (free and
protein-bound) ADM (V----V) in patients receiving 100mg
m'2 (a, patient number 11, infusion time 45 min) and
120mg m2 (b, patient number 9, infusion time 65 min) of
L-ADM. The delayed rise in plasma drug levels in patient
number 9 is probably due to a technical problem that reduced the
drip rate during the first 20 min of infusion.
Table III Plasma ADM in liposome-associated form in patients receiving L-ADMa
Liposome-associated Nonliposome-associated
Patient Dose AUC time AUC Peak level AUC Peak level AUC Peak level Involvement
number mgm2 span (h) mg h l' mgl' mg h1-f mgl' ratio ratio ofliverb
11 100 1.83 3.1 5.2 <0.1 <0.1 >10 >10 0
6 85 2.00 4.6 5.4 <0.1 <0.1 >10 >10 I
8 120 1.67 1.3 2.1 <0.1 <0.1 >10 >10 0
5 85 1.75 1.4 1.8 0.2 0.4 7.0 4.5 II
7 100 2.50 1.6 2.2 0.4 0.9 4.0 2.4 II
10 120 2.33 3.3 4.0 2.4 2.4 1.4 1.7 Lobectomy
9 120 2.08 1.7 2.4 1.2 1.9 1.4 1.3 III
'AUC calculated by the trapezoidal rule along the indicated time span; bo = no hepatic involvement; I = <25%
hepatic replacement; II = 25-75% hepatic replacement; III = >75% hepatic replacement (van de Velde, 1986).
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In an attempt to follow simultaneously the processes of
liposome clearance and drug leakage, we measured the
plasma concentrations of a liposome constituent, PG, and
that of liposome-associated ADM in three patients during
and after infusion of L-ADM. Figure 4 shows that the
plasma clearances of PG and liposome-associated drug in
patient number 10, receiving 120 mg m2 L-ADM, were
rapid in both cases. However, the per cent ofinjected dose of
PG was consistently higher than that of liposome-associated
drug at all time points. The L-ADM to PG molar ratio
depicted in the inset of Figure 4 points at an initial sharp
drop from the pre-infusion value (0.181 at time 0, down to
0.078 at 20 min into the infusion) followed by a slower
decline at later time points. This suggests that a sizeable
fraction of drug leaks from the liposomes immediately upon
infusion. Thereafter, drug leakage proceeds at a slower rate.
Similar results were obtained in patients numbers 6 and 7,
receiving 85 and lOOmg m-2 respectively.
Imaging studies
The stability of DF-containing "'In-radiolabelled liposomes
was checked by in vitro incubation in plasma at 37°C for
10 min. The sample was then passed through a Biogel A15M
column (Druckmann et al., 1989) and the radioactivity of
each fraction was counted in a Gamma counter. As seen in
Figure 5a, most of the radioactivity is recovered in the initial
fractions (void volume) where the liposomes are eluted.
About 20% of the radiolabel is bound by plasma proteins
and eluted in a second peak. In contrast, when the free label,
"'In-oxine, is incubated with plasma, essentially all the label
becomes bound to proteins as seen in the elution profile.
When plasma samples of patients injected with radio-
labelled liposomes are fractionated using a Biogel A1SM
column, the pattern of elution (Figure Sb) is similar to that
obtained after in vitro incubation of radiolabelled liposomes
with plasma. The fraction of radiolabel bound to plasma
proteins is probably the result of exchange of bilayer-assoc-
iated "'In-oxine into metal-binding plasma proteins such as
transferrin (Moerlein & Welch, 1981). In addition, leakage of
"'In-DF from the water compartment of circulating lipo-
somes and metal translocation to transferrin may also occur,
although, given the fast clearance of these liposomes by the
RES, this phenomenon is likely to be of limited significance.
Nine cancer patients were imaged with radiolabelled lipo-
somes. In seven of them, the label was found to concentrate
heavily in liver and spleen within minutes after injection with
no major change in appearance in later films (Figure 6). In
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Figure 4 Plasma levels of PG (-) and liposome-associated
ADM (0) in patient number 10 receiving 120mgm-' L-ADM in
a 78 min infusion. The inset figure depicts the molar ratio of
liposome-associated ADM to PG at pre-infusion level (time 0)
and after administration to the patient.
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Figure 5 Biogel A15M elution profile in "'In. a, in vitro incuba-
tion in human plasma of free "'In-oxine (O--O) and "'In-
labelled, DF-containing liposomes (0-0). b, plasma sample
10 min after in vivo administration of "'In-labelled, DF-con-
taining liposomes in patient number 13. Liposome standards elute
in fractions 4-5, plasma proteins in fractions 8-10, and free
"'In-DF in fraction 11.
Figure 6 Whole body scintigraphy with "'In-labelled liposomes
in patient number 10, 24 h after injection. Lt side, anterior view;
Rt side, posterior view. Note biodistribution in the RES with
prominent uptake in liver and spleen and minimal uptake in the
skeletal bone marrow.
addition, limited uptake by the skeletal bone marrow was
observed in most cases. In two patients with hepatitis B virus
(HBV)-related active hepatitis and advanced hepatocellular
carcinoma, liposome uptake by the liver was markedly inhib-
ited and delayed, while localisation in the bone marrow was
significantly enhanced (Figure 7). No significant uptake in
intrahepatic or extrahepatic tumours was found (Figures 8
and 9), except for one of the hepatoma patients. In the latter
patient (number 15) who responded favourably to chemo-
therapy (Table I), there was a faint but still important uptake
a
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Figure 7 Whole body scintigraphy with "'In-labelled liposomes
in patient number 12 at 24 h after injection. Note the quasi-
absence of uptake in the liver area and the prominent uptake in
the enlarged spleen and in the skeletal bone marrow. This patient
suffered from hepatoma and underlying HBV-positive active
hepatitis.
Figure 9 Upper half-body anterior view of scintigraphy with
"'In-labelled liposomes in patient number 19, 2 h after injection.
A palpable, metastatic, subcutaneous mass of 5 cm diameter on
the left side of the sternal manubrium (see arrow) is seen as a
filling defect. In contrast, there is marked uptake by the normal
skeletal bone marrow and spleen (only upper part shown). Note
that liver uptake was minimal in this patient who suffered from
hepatoma and underlying chronic hepatitis.
Figure 8 Liver scintigraphies (right anterior-oblique views) in
patient number 14, 2h after injection of the labels. Lt side,
"'In-labelled liposomes; Rt side, 9'Tc tin colloid. Identical filling
defects are seen in both scintigraphies.
by the tumour involved, left hepatic lobe (Figure 10). On
autopsy, diffuse involvement of the left hepatic lobe by
hepatocellular carcinoma was found in this patient. There
was a remarkable similarity between the images obtained
with 9'Tc tin colloid liver-spleen scans and those obtained
with "'In-radiolabelled liposomes (Figure 8). The clinical
implications of the imaging results should however be
cautiously interpreted since the organ distribution of "'In-
labelled liposomes is only a partial representation of the
distribution of L-ADM, the latter being affected by the rate
of ADM leakage as shown above.
Discussion
This is the first study in which a complete pharmacokinetic-
biodistribution analysis of a drug-liposome dosage form in
human patients is described. The clearance of ADM when
delivered as L-ADM is a composite of two processes: (i)
clearance of liposomes containing ADM in the RES, pre-
dominantly liver and spleen; and (ii) clearance of ADM
released from liposomes in plasma. The analysis which
includes total drug, liposome-associated drug and liposome
markers suggests that both processes operate in human
patients and that factors such as the patient's liver function
may affect their relative contribution.
Delivery of ADM in liposome-entrapped form has been
proposed as a means to reduce the toxicity of ADM and
improve its therapeutic index based on a number of pre-
clinical studies (reviewed in Perez-Soler, 1989; Gabizon,
Figure 10 Hepatosplenic scintigraphy (anterior view) in patient
number 15, 2 h after injection of "'In-labelled liposomes. Note
that the uptake of the left liver lobe is reduced but still signi-
ficant. The tumour involvement of the left liver lobe was patho-
logically documented (see text). The spleen is enlarged as a result
of cirrhosis.
1989). Phase I clinical studies have been carried out with
three formulations of L-ADM (Gabizon et al., 1989a;
Creaven et al., 1990; Rahman et al., 1990). In all three
studies, the dose-limiting toxicity has been myelosuppression.
With the present formulation of L-ADM, the MTD and the
recommended dosage for phase II studies are 120 and
100 mg m- respectively (Gabizon et al., 1989a), which are
somewhat greater than the MTD (90 mg m-2 split in 3 con-
secutive days) and recommended dosage of free ADM
(75 mgm2) as single agent in the 21-day schedule (Midd-LIPOSOME-ASSOCIATED ADRIAMYCIN IN CANCER PATIENTS 1131
leman et al., 1971; O'Bryan et al., 1973). The present study
suggests that the reduced clinical toxicity of L-ADM results
from relative changes in the tissue distribution of the drug,
with a partial shift toward drug accumulation in the RES at
the expense of other tissues.
The main limitations of a therapeutic strategy based on
L-ADM, as revealed by this study, are significant drug leak-
age and preferential RES uptake. These shortcomings are
probably the result of some of the formulation characteris-
tics, such as: (i) Drug entrapment in the bilayer as opposed
to the liposome aqueous interior. Bilayer-associated drug
may be more accessible to exchange with plasma proteins
and the external aqueous phase (Goren et al., 1990). This
process will be affected by the degree of dilution upon injec-
tion which is also dependent on the mode of administration
(greater dilution effect for infusion than for bolus). The
association of ADM with liposomes is related to the associ-
ation constant which determine the liposome/medium or
liposome/plasma partition coefficient (Kp). Thus, even in the
presence of a high Kp, drug leakage may still occur due to
the large increase in aqueous phase volume upon infusion
(>1,000-fold). The observation of a sudden burst of drug
leakage shortly after injection (Figure 4) is compatible with
the dilution effect. (ii) The presence of a high molar ratio of
PG in the liposome bilayer which may accelerate uptake by
the RES (Gabizon & Papahadjopoulous, 1988). (iii) A vesicle
size too large to allow for extravasation (Hwang, 1987).
To account for the dose-limiting bone marrow toxicity
observed with L-ADM, the following mechanisms should be
considered:
(a) Drug leakage from circulating liposomes. There is ex-
perimental evidence for this process as shown here.
However, its quantitative significance may vary and
appears to be related to the rate of RES clearance.
When RES clearance is slow due to severe liver dysfunc-
tion, drug leakage becomes more important.
(b) Liposome localisation in the bone marrow. As with (a),
an impaired hepatic clearance will enhance this process
as suggested in Figure 7. Bone marrow uptake is simi-
larly increased in cirrhotic patients injected with 9'Tc
tin colloid for liver-spleen scans and in animal studies in
which the liver is saturated with large pre-doses of
unlabelled liposomes (Poste, 1983). However, it remains
unclear whether this process can significantly increase
drug delivery to the bone marrow, since liposomes cir-
culating for a long period oftime may have lost most of
their drug payload as shown in Figure 4.
(c) Systemic release of drug stored in the RES. Animal
experiments suggest that a fraction of this drug pool
may be released back into the circulation in an active
form (Storm et al., 1987), which could damage hemato-
poyetic cells and partially contribute to myelosuppres-
sion.
In view of the changes in tissue distribution and bioavail-
ability, it is uncertain whether the increased tolerated dosage
of L-ADM will result in enhanced antitumour activity. In
agreement with the human liposome imaging studies reported
by Richardson et al. (1979), the liposomes used here are
cleared very quickly by the RES of liver and spleen and to a
lesser extent by the bone marrow. Our studies suggest that
the mechanism of antitumour activity of L-ADM is complex,
and presumably results from exposure of tumour cells to
drug leaking from circulating liposomes and drug released
from the RES. Obviously, drug leakage from circulating
liposomes is undesirable since it increases toxicity. Regarding
drug release from the RES, the clinical conditions most likely
to benefit from this approach are tumours diffusely infiltrat-
ing the liver parenchyma or sinusoids, spleen, and bone
marrow, such as lymphomas and, in some instances, small
cell lung carcinoma (MacSween et al., 1979; Bassermann,
1986). This is also supported by preclinical work demon-
strating the pharmacologic and therapeutic advantages of
L-ADM in lymphoma models infiltrating liver and spleen
(Mayhew et al., 1983; Gabizon et al., 1983, 1985). In con-
trast, solid tumours produce liver nodules without sinusoids
and without Kupffer cells (MacSween et al., 1979), except for
a small fraction of hepatomas in which tumour cell trabe-
culae are lined by sinusoids (Noltenius, 1981). Thus, in most
solid tumours, drug exposure in relation to dosage may be
suboptimal.
Factors such as RES/liver function, site of tumour involve-
ment, and proximity of tumour cells to RES cells may have
an important effect on the antitumour response and will
require special consideration in the design of further clinical
studies with the present formulation of L-ADM and other
liposome formulations having similar pharmacokinetic pro-
perties. These results however should not be extrapolated to
liposome preparations with different pharmacokinetic proper-
ties, RES affinity, and tumour localisation features (Forssen,
1988; Gabizon et al., 1989b).
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